Introduction: Atopic dermatitis (AD) is a physical, emotional, and social burden for patients. Most suffer from itching, pain, and dry skin as well as sleep disturbances, experienced stigmatization, anxiety, or depression. Therefore, it is important to consider the psychosocial well-being and also stigmatization in the treatment of people with AD. The aims of this study were to compare clinical and psychosocial parameters between patients with a different severity of AD and to analyse the effect of an omega-6-fatty-acid-skin therapy. Methods: Adult patients with clinically confirmed AD were asked about quality of life, stigmatization, and well-being after dermatological diagnosis. A second examination took place after 2–5 weeks. Meanwhile, after randomization, half of the patients used an omega-6-fatty-acid-skin therapy. Results: Seventy-nine patients were included in the study. The use of omega-6-fatty-acid-skin therapy resulted in a significant reduction in the severity of xerosis cutis compared to patients using another basic therapy. In addition, the health-related quality of life of all patients improved significantly in both groups (F = 7.56; p = 0.008), and no significant difference was found between the groups over time in the patient-reported outcomes. Conclusion: Basic therapy for AD leads to relevant improvements in clinical status as well as quality of life. Patients using omega-6-fatty-acid-skin therapy experience greater improvement in xerosis cutis compared to free-choice basic therapy.

1.
Radtke
MA
,
Schäfer
I
,
Glaeske
G
,
Jacobi
A
,
Augustin
M
.
Prevalence and comorbidities in adults with psoriasis compared to atopic eczema
.
J Eur Acad Dermatol Venereol
.
2017
;
31
(
1
):
151
7
. .
2.
Augustin
M
,
Herberger
K
,
Hintzen
S
,
Heigel
H
,
Franzke
N
,
Schäfer
I
.
Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers
.
Br J Dermatol
.
2011
;
165
(
4
):
865
73
. .
3.
Augustin
M
,
Glaeske
G
,
Hagenström
K
.
Neurodermatitis Report. Prevention, care and innovation
.
Hamburg
:
Universitätsklinik Hamburg-Eppendorf/Bremen: Universität Bremen
;
2021
.
4.
Augustin
M
,
Kirsten
N
,
Körber
A
,
Wilsmann-Theis
D
,
Itschert
G
,
Staubach-Renz
P
, et al
.
Prevalence, predictors and comorbidity of dry skin in the general population
.
J Eur Acad Dermatol Venereol
.
2019
;
33
(
1
):
147
50
. .
5.
Augustin
M
,
Langenbruch
A
,
Blome
C
,
Gutknecht
M
,
Werfel
T
,
Ständer
S
, et al
.
Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation
.
J Eur Acad Dermatol Venereol
.
2020
;
34
(
1
):
142
52
. .
6.
Kwatra
SG
,
Gruben
D
,
Fung
S
,
DiBonaventura
M
.
Psychosocial comorbidities and health status among adults with moderate-to-severe atopic dermatitis: a 2017 US national health and wellness survey analysis
.
Adv Ther
.
2021
;
38
(
3
):
1627
37
. .
7.
von Stülpnagel
CC
,
Augustin
M
,
Da Silva
N
,
Schmidt
L
,
Nippel
G
,
Sommer
R
.
Exploring the burden of xerosis cutis and the impact of dermatological skin care from patient’s perspective
.
J Dermatolog Treat
.
2022
;
33
(
5
):
2482
7
. .
8.
Werfel
T
,
Aberer
W
,
Ahrens
F
,
Augustin
M
,
Biedermann
T
,
Diepgen
T
, et al
.
Guideline Neurodermatitis atopic eczema; atopic dermatitis
.
J Dtsch Dermatol Ges
.
2016
;
14
(
1
):
e1
75
. .
9.
Werfel
T
,
Heratizadeh
A
,
Aberer
W
,
Ahrens
F
,
Augustin
M
,
Biedermann
T
, et al
.
Aktualisierung “Systemtherapie bei Neurodermitis” zur S2k-Leitlinie Neurodermitis
.
J Dtsch Dermatol Ges
.
2021
;
19
(
1
):
151
69
. .
10.
Wollenberg
A
,
Kinberger
M
,
Arents
B
,
Aszodi
N
,
Avila Valle
G
,
Barbarot
S
, et al
.
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
.
J Eur Acad Dermatol Venereol
.
2022
;
36
(
9
):
1409
31
. .
11.
Wohlrab
J
,
Staubach
P
,
Augustin
M
,
Eisert
L
,
Hünerbein
A
,
Nast
A
, et al
.
S2k guidelines for the use of topical preparations on the skin
.
J Dtsch Dermatol Ges
.
2018
;
16
(
3
):
376
92
. .
12.
Augustin
M
,
Wilsmann-Theis
D
,
Körber
A
,
Kerscher
M
,
Itschert
G
,
Dippel
M
, et al
.
Positionspapier: diagnostik und Therapie der Xerosis cutis
.
J Dtsch Dermatol Ges
.
2018
;
16
(
Suppl 4
):
3
35
. .
13.
World Medical Association
.
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects
.
JAMA
.
2013
;
310
(
20
):
2191
4
. .
14.
Sommer
R
,
Augustin
M
,
Da Silva
N
,
von Stülpnagel
CC
.
Development and validation of an outcome instrument measuring dry skin: the Xerosis Area and Severity Index (XASI)
.
J Eur Acad Dermatol Venereol
.
2022
;
36
(
1
):
e70
2
. .
15.
European Task Force on Atopic Dermatitis
.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis
.
Dermatology
.
1993
;
186
(
1
):
23
31
. .
16.
Hanifin
JM
,
Thurston
M
,
Omoto
M
,
Cherill
R
,
Tofte
SJ
,
Graeber
M
.
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group
.
Exp Dermatol
.
2001
;
10
(
1
):
11
8
. .
17.
Finlay
AY
,
Khan
GK
.
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
.
Clin Exp Dermatol
.
1994
;
19
(
3
):
210
6
. .
18.
World Health Organization (WHO)
.
Division of mental health and prevention of substance abuse. World Health Organization
:
WHOQOL User Manual
;
2012
.
19.
Löwe
B
,
Kroenke
K
,
Gräfe
K
.
Detecting and monitoring depression with a two-item questionnaire (PHQ-2)
.
J Psychosom Res
.
2005
;
58
(
2
):
163
71
. .
20.
Kroenke
K
,
Spitzer
RL
,
Williams
JBW
,
Monahan
PO
,
Löwe
B
.
Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection
.
Ann Intern Med
.
2007
;
146
(
5
):
317
25
. .
21.
Lawrence
JW
,
Fauerbach
JA
,
Heinberg
LJ
,
Doctor
M
,
Thombs
BD
.
The reliability and validity of the Perceived Stigmatization Questionnaire (PSQ) and the Social Comfort Questionnaire (SCQ) among an adult burn survivor sample
.
Psychol Assess
.
2006
;
18
(
1
):
106
11
. .
22.
Müller
A
,
Smits
D
,
Claes
L
,
Jasper
S
,
Berg
L
,
Ipaktchi
R
, et al
.
Validation of the German version of the perceived stigmatization questionnaire/social comfort questionnaire in adult burn survivors
.
Burns
.
2016
;
42
(
4
):
790
6
. .
23.
Stangier
U
,
Janich
C
,
Adam-Schwebe
S
,
Berger
P
,
Wolter
M
.
Screening for body dysmorphic disorder in dermatological outpatients
.
Dermatol Psychosom
.
2003
;
4
(
2
):
66
71
. .
24.
von Stülpnagel
CC
,
Augustin
M
,
Düpmann
L
,
Da Silva
N
,
Sommer
R
.
Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases: a systematic review
.
J Eur Acad Dermatol Venereol
.
2021
;
35
(
11
):
2166
84
. .
25.
Del Rosso
JQ
.
Repair and maintenance of the epidermal barrier in patients diagnosed with atopic dermatitis: an evaluation of the components of a body wash-moisturizer skin care regimen directed at management of atopic skin
.
J Clin Aesthet Dermatol
.
2011
;
4
(
6
):
45
55
.
26.
Langenbruch
A
,
Radtke
M
,
Franzke
N
,
Ring
J
,
Foelster-Holst
R
,
Augustin
M
.
Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth
.
J Eur Acad Dermatol Venereol
.
2014
;
28
(
6
):
719
26
. .
27.
Wollenberg
A
,
Oranje
A
,
Deleuran
M
,
Simon
D
,
Szalai
Z
,
Kunz
B
, et al
.
ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients
.
J Eur Acad Dermatol Venereol
.
2016
;
30
(
5
):
729
47
. .
28.
Knop
M
,
Gürtler
A
,
Heratizadeh
A
,
Aszodi
N
,
Werfel
T
,
Wollenberg
A
.
External therapy of atopic eczema
.
Hautarzt
.
2018
;
69
(
3
):
210
6
. .
You do not currently have access to this content.